TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity

Nature Medicine

Volumn 13, Issue 5, 2007, Pages 543-551

  Baccala, Roberto ^a   Hoebe, Kasper ^a   Kono, Dwight H ^a   Beutler, Bruce ^a   Theofilopoulos, Argyrios N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIGEN; AUTOANTIBODY; BETA INTERFERON; INTERFERON; LIGAND; NUCLEIC ACID; TOLL LIKE RECEPTOR;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DENDRITIC CELL; DISEASE ASSOCIATION; GENETIC ANALYSIS; HUMAN; IMMUNOSTIMULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, IMMUNOLOGICAL; TOLL-LIKE RECEPTORS;

EID: 34249707811     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1590     Document Type: Review

References (101)

1. Kono, D.H., Baccala, R. & Theofilopoulos, A.N. Genes and genetics of murine lupus. in Systemic Lupus Erythematosus (ed. Lahita, R.G.) 225-263 (Academic Press, San Diego, 2004).
2. Goodnow, C.C., Sprent, J., Fazekas de St Groth, B. & Vinuesa, C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435, 590-597 (2005).
3. Honda, K. & Taniguchi, T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6, 644-658 (2006).
4. Platanias, L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386 (2005).
5. Liu, Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275-306 (2005).
6. Theofilopoulos, A.N., Baccala, R., Beutler, B. & Kono, D.H. Type I interferons (/) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307-335 (2005).
7. Banchereau, J. & Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25, 383-392 (2006).
8. Zhuang, H. et al. Lupus-like disease and high interferon levels corresponding to trisomy of the type I interferon cluster on chromosome 9p. Arthritis Rheum. 54, 1573-1579 (2006).
9. Sigurdsson, S. et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76, 528-537 (2005).
10. Graham, R.R. et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 38, 550-555 (2006).
11. Santiago-Raber, M.L. et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197, 777-788 (2003).
12. Braun, D., Geraldes, P., Demengeot, J. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 20, 15-25 (2003).
13. Hron, J.D. & Peng, S.L. Type I IFN protects against murine lupus. J. Immunol. 173, 2134-2142 (2004).
14. Schwarting, A. et al. Interferon-β: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J. Am. Soc. Nephrol. 16, 3264-3272 (2005).
15. Baccala, R., Kono, D.H. & Theofilopoulos, A.N. Interferons as pathogenic effectors in autoimmunity. Immunol. Rev. 204, 9-26 (2005).
16. Zhu, J. et al. T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J. Clin. Invest. 115, 1869-1878 (2005).
17. Chen, M. et al. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 311, 1160-1164 (2006).
18. Le Bon, A. et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176, 2074-2078 (2006).
19. Lin, Q., Dong, C. & Cooper, M.D. Impairment of T and B cell development by treatment with a type I interferon. J. Exp. Med. 187, 79-87 (1998).
20. Kawai, T. & Akira, S. TLR signaling. Cell Death Differ. 13, 816-825 (2006).
21. Beutler, B. et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 24, 353-389 (2006).
22. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995 (2004).
23. Fitzgerald, K.A. & Chen, Z.J. Sorting out Toll signals. Cell 125, 834-836 (2006).
24. Liew, F.Y., Xu, D., Brint, E.K. & O'Neill, L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5, 446-458 (2005).
25. O'Neill, L.A. DisSARMing Toll-like receptor signaling. Nat. Immunol. 7, 1023-1025 (2006).
26. Meylan, E. & Tschopp, J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell 22, 561-569 (2006).
27. Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
28. Hornung, V. et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314, 994-997 (2006).
29. Pichlmair, A. et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′ phosphates. Science 314, 997-1001 (2006).
30. Gitlin, L. et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. USA 103, 8459-8464 (2006).
31. Yoneyama, M. et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 175, 2851-2858 (2005).
32. Rothenfusser, S. et al. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J. Immunol. 175, 5260-5268 (2005).
33. Stetson, D.B. & Medzhitov, R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 24, 93-103 (2006).
34. Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823-835 (2006).
35. Ronnblom, L., Eloranta, M.L. & Alm, G.V. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 54, 408-420 (2006).
36. Vollmer, J. et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202, 1575-1585 (2005).
37. Barrat, F.J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131-1139 (2005).
38. Savarese, E. et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107, 3229-3234 (2006).
39. Martin, D.A. & Elkon, K.B. Autoantibodies make a U-turn: the toll hypothesis for auto-antibody specificity. J. Exp. Med. 202, 1465-1469 (2005).
40. Wagner, H. Endogenous TLR ligands and autoimmunity. Adv. Immunol. 91, 159-173 (2006).
41. Boule, M.W. et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199, 1631-1640 (2004).
42. Means, T.K. et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115, 407-417 (2005).
43. Sano, H.& Morimoto, C. Dna isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content. J. Immunol. 128, 1341-1345 (1982).
44. Ishii, K.J. et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 7, 40-48 (2006).
45. Martin, D.A. & Elkon, K.B. Intracellular mammalian DNA stimulates myeloid dendritic cells to produce type I interferons predominantly through a toll-like receptor 9-independent pathway. Arthritis Rheum. 54, 951-962 (2006).
46. Decker, P., Singh-Jasuja, H., Haager, S., Kotter, I. & Rammensee, H.G. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J. Immunol. 174, 3326-3334 (2005).
47. Cortez-Gonzalez, X. et al. TLR9-independent activation of B lymphocytes by bacterial DNA. DNA Cell Biol. 25, 253-261 (2006).
48. Sun, Q. et al. The specific and essential role of MAVS in antiviral innate immune responses. Immunity 24, 633-642 (2006).
49. Napirei, M. et al. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 25, 177-181 (2000).
50. Tsukumo, S. & Yasutomo, K. DNaseI in pathogenesis of systemic lupus erythematosus. Clin. Immunol. 113, 14-18 (2004).
51. Bodano, A., Amarelo, J., Gonzalez, A., Gomez-Reino, J.J. & Conde, C. Novel DNASE I mutations related to systemic lupus erythematosus. Arthritis Rheum. 50, 4070-4071 (2004).
52. Yoshida, H., Okabe, Y., Kawane, K., Fukuyama, H. & Nagata, S. Lethal anemia caused by interferon- produced in mouse embryos carrying undigested DNA. Nat. Immunol. 6, 49-56 (2005).
53. Okabe, Y., Kawane, K., Akira, S., Taniguchi, T. & Nagata, S. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J. Exp. Med. 202, 1333-1339 (2005).
54. Kawane, K. et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 443, 998-1002 (2006).
55. Janssen, E. et al. Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway. Immunity 24, 787-799 (2006).
56. Fritz, J.H., Ferrero, R.L., Philpott, D.J. & Girardin, S.E. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 7, 1250-1257 (2006).
57. Andrade, F., Casciola-Rosen, L. & Rosen, A. Apoptosis in systemic lupus erythematosus. Clinical implications. Rheum. Dis. Clin. North Am. 26, 215-227, v (2000).
58. Gaipl, U.S. et al. Inefficient clearance of dying cells and autoreactivity. Curr. Top. Microbiol. Immunol. 305, 161-176 (2006).
59. Ogden, C.A. & Elkon, K.B. Role of complement and other innate immune mechanisms in the removal of apoptotic cells. Curr. Dir. Autoimmun. 9, 120-142 (2006).
60. Botto, M. et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19, 56-59 (1998).
61. Lu, Q. & Lemke, G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293, 306-311 (2001).
62. Mevorach, D., Zhou, J.L., Song, X. & Elkon, K.B. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J. Exp. Med. 188, 387-392 (1998).
63. Denny, M.F. et al. Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J. Immunol. 176, 2095-2104 (2006).
64. Takemura, Y. et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J. Clin. Invest. 117, 375-386 (2007).
65. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249-1255 (1999).
66. Winau, F. et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24, 105-117 (2006).
67. Albert, M.L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
68. Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007).
69. Waldner, H., Collins, M. & Kuchroo, V.K. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 113, 990-997 (2004).
70. Lang, K.S. et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11, 138-145 (2005).
71. Lang, K.S. et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 116, 2456-2463 (2006).
72. Eriksson, U. et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat. Med. 9, 1484-1490 (2003).
73. Krieg, A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002).
74. Seya, T. et al. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res. 23, 4369-4376 (2003).
75. Poole, B.D., Scofield, R.H., Harley, J.B. & James, J.A. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 39, 63-70 (2006).
76. Pawar, R.D., Patole, P.S., Wornle, M. & Anders, H.J. Microbial nucleic acids pay a Toll in kidney disease. Am. J. Physiol. Renal Physiol. 291, F509-F516 (2006).
77. Mathian, A., Weinberg, A., Gallegos, M., Banchereau, J. & Koutouzov, S. IFN- induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J. Immunol. 174, 2499-2506 (2005).
78. Mohty, M. et al. IFN- skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J. Immunol. 171, 3385-3393 (2003).
79. Bekeredjian-Ding, I.B. et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174, 4043-4050 (2005).
80. Hang, L. et al. Induction of murine autoimmune disease by chronic polyclonal B cell activation. J. Exp. Med. 157, 874-883 (1983).
81. Christensen, S.R. et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202, 321-331 (2005).
82. Ehlers, M., Fukuyama, H., McGaha, T.L., Aderem, A. & Ravetch, J.V. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203, 553-561 (2006).
83. Wu, X. & Peng, S.L. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 54, 336-342 (2006).
84. Lartigue, A. et al. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J. Immunol. 177, 1349-1354 (2006).
85. Yu, P. et al. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int. Immunol. 18, 1211-1219 (2006).
86. Christensen, S.R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428 (2006).
87. Bagavant, H., Deshmukh, U.S., Gaskin, F. & Fu, S.M. Lupus glomerulonephritis revisited 2004: autoimmunity and end-organ damage. Scand. J. Immunol. 60, 52-63 (2004).
88. Avrameas, S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol. Today 12, 154-159 (1991).
89. Lau, C.M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171-1177 (2005).
90. Berland, R. et al. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 25, 429-440 (2006).
91. Pisitkun, P. et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312, 1669-1672 (2006).
92. Subramanian, S. et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. USA 103, 9970-9975 (2006).
93. Tabeta, K. et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol. 7, 156-164 (2006).
94. Maldonado, M.A. et al. The role of environmental antigens in the spontaneous development of autoimmunity in MRL-lpr mice. J. Immunol. 162, 6322-6330 (1999).
95. Dong, L., Ito, S., Ishii, K.J. & Klinman, D.M. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum. 52, 651-658 (2005).
96. Rezaei, N. Therapeutic targeting of pattern-recognition receptors. Int. Immunopharmacol. 6, 863-869 (2006).
97. Nordmark, G., Alm, G.V. & Ronnblom, L. Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat. Clin. Pract. Rheumatol. 2, 262-269 (2006).
98. Stewart, T.A. Neutralizing interferon as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev. 14, 139-154 (2003).
99. Nestle, F.O. et al. Plasmacytoid predendritic cells initiate psoriasis through interferon- production. J. Exp. Med. 202, 135-143 (2005).
100. + lymphocytes in dermatomyositis. Clin. Exp. Dermatol. 31, 576-582 (2006).
101. Ishii, K.J., Uematsu, S. & Akira, S. 'Toll' gates for future immunotherapy. Curr. Pharm. Des. 12, 4135-4142 (2006).